<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02860052</url>
  </required_header>
  <id_info>
    <org_study_id>NI-AF201</org_study_id>
    <nct_id>NCT02860052</nct_id>
  </id_info>
  <brief_title>SB208 for the Treatment of Tinea Pedis</brief_title>
  <official_title>A Phase 2 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Dose-Ranging Study Assessing Efficacy and Safety of SB208 and Vehicle Gel in Subjects With Interdigital Tinea Pedis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novan, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novan, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2, multi-center, double-blind, randomized, vehicle-controlled study to be
      conducted in approximately 170 non immunocompromised adult subjects with interdigital tinea
      pedis. Subjects will apply the investigational product (IP) (SB208 or Vehicle Gel) to the
      interdigital areas and all affected and immediate surrounding areas of one or both feet once
      daily for 2 weeks, followed by a 4-week post-treatment observation period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 19, 2016</start_date>
  <completion_date type="Actual">February 1, 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fungal culture result</measure>
    <time_frame>2 weeks</time_frame>
    <description>Negative fungal culture from target lesion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical cure</measure>
    <time_frame>6 wks</time_frame>
    <description>Amelioration of signs and symptoms of tinea pedis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mycological cure</measure>
    <time_frame>6 wks</time_frame>
    <description>No evidence of fungal infection based on skin scraping and culture</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>6 weeks</time_frame>
    <description>Summary of treatment emergent adverse events by treatment group</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">222</enrollment>
  <condition>Tinea Pedis</condition>
  <arm_group>
    <arm_group_label>SB208 2%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SB208 4%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SB208 16%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB208 2%</intervention_name>
    <description>SB208 2% once daily</description>
    <arm_group_label>SB208 2%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB208 4%</intervention_name>
    <description>SB208 4% once daily</description>
    <arm_group_label>SB208 4%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB208 16%</intervention_name>
    <description>SB208 16% once daily</description>
    <arm_group_label>SB208 16%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Gel</intervention_name>
    <description>Vehicle Gel once daily</description>
    <arm_group_label>Vehicle Gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Otherwise healthy male and female subjects with clinical diagnosis of interdigital t.
             pedis

          -  T.pedis provisionally confirmed at baseline by a positive KOH wet mount for segmented
             fungal hyphae on skin scraping from the target site

        Exclusion Criteria:

          -  Women who are pregnant or nursing or planning on becoming pregnant

          -  Subjects with onychomycosis or moccasin-type t. pedis

          -  Subjects using topical or systemic anti-fungal agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M Joyce Rico, MD</last_name>
    <role>Study Director</role>
    <affiliation>Novan, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Dermatológico y Cirugía de Piel,</name>
      <address>
        <city>Santo Domingo</city>
        <country>Dominican Republic</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Dominican Republic</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2016</study_first_submitted>
  <study_first_submitted_qc>August 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2016</study_first_posted>
  <last_update_submitted>December 14, 2017</last_update_submitted>
  <last_update_submitted_qc>December 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinea</mesh_term>
    <mesh_term>Tinea Pedis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

